Analytical Comparison: Uranium Energy Corp. (UEC) vs. At Intellia Therapeutics, Inc. (NTLA)

The shares of Uranium Energy Corp. have decreased by more than -19.20% this year alone. The shares recently went up by 4.11% or $0.04 and now trades at $1.01. The shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA), has jumped by 11.43% year to date as of 09/11/2019. The shares currently trade at $15.21 and have been able to report a change of 15.05% over the past one week.

The stock of Uranium Energy Corp. and Intellia Therapeutics, Inc. were two of the most active stocks on Wednesday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.

Profitability and Returns

Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. These figures suggest that UEC ventures generate a higher ROI than that of NTLA.

Liquidity and Financial Risk

The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for UEC is 15.40 and that of NTLA is 8.00. This implies that it is easier for UEC to cover its immediate obligations over the next 12 months than NTLA. The debt ratio of UEC is 0.24 compared to 0.02 for NTLA. UEC can be able to settle its long-term debts and thus is a lower financial risk than NTLA.


UEC currently trades at a P/B of 2.30, while NTLA trades at a P/B of 2.52, and a P/S of 20.37. This means that looking at the earnings, book values and sales basis, UEC is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.

Analyst Price Targets and Opinions

The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of UEC is currently at a -69.11% to its one-year price target of 3.27. Looking at its rival pricing, NTLA is at a -46.35% relative to its price target of 28.35.

When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), UEC is given a 1.80 while 1.90 placed for NTLA. This means that analysts are more bullish on the outlook for NTLA stocks.

Insider Activity and Investor Sentiment

Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for UEC is 13.44 while that of NTLA is just 14.59. This means that analysts are more bullish on the forecast for UEC stock.


The stock of Intellia Therapeutics, Inc. defeats that of Uranium Energy Corp. when the two are compared, with NTLA taking 2 out of the total factors that were been considered. NTLA happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, NTLA is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for NTLA is better on when it is viewed on short interest.